Reverse-engineering Nature

Improving health outcomes in innovative ways based on Nature’s wisdom

About The Company

With an aging population and a growing focus in healthcare issues, biomedical science has becoming increasingly vital more than ever. Global BioLife is a subsidiary of Singapore eDevelopment Limited, a company listed at Singapore Exchange Securities Trading Limited (“SGX-ST”). Global BioLife strives to leverage its scientific know-how and Intellectual Property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of Global Research & Discovery Group Sciences (“GRDGS”) and Holista Colltech (Australia) Limited (“Holista”), Global BioLife pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. We are also collaborating with our partners to develop 2nd generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue.
Board of Directors
Chan Heng Fai Executive Chairman
Dr Rajen Manicka Director
Daryl L. Thompson Director of Scientific Initiatives

Global Health Initiative

Global BioLife actively engaged in changing the game of healthcare. Our directives are to:
  • Create a universal drug that is effective at treating multiple diseases
  • Create a drug that can universally boost the safety and efficacy of existing medications
  • Create a drug that can actively surmount and defeat enzymatic, viral, parasitic, and bacterial defense systems that allow for them to become resistant to traditional medications, extending the therapeutic activity of existing drugs.

Research & Development

Continual research and development is the key foundation of Global BioLife. Most of the research work will be accomplished together with GRDGS, which is a natural products discovery drug research company set up by pioneering natural products scientist, Daryl Thompson. Based in Florida, he has been twice nominated for the Nobel Prize for his work in cutting-edge organic and carbohydrate chemistry. He has a successful record of developing and patenting technologies in the healthcare and related food industries. Among these, he developed and branded an internationally patented natural-based therapeutic formula for diabetes and obesity, trademarked as Emulin®. He also designed a non-invasive medical device to measure blood glucose levels for the Diabetes Resource Center which earned the Diabetes World Humanitarian Award in 1998. Mr Thompson also has had the experience of working with the United States Army Medical Research Institute of Infectious Diseases (“USAMRIID”). Most recently, the United States patent office fast-tracked a patent in his name for defense against neurological disease. This patent will be a lead project to be developed by Global BioLife.
Space Technologies
  • Hibernation
  • Radiation Protection
  • Bio-pharming
Food Sciences
  • Radioprotectant
  • Neurologics
  • Performance Enhancement
  • Metabolic
  • Cold/Flu
Emerging Pandemic Protection Studies
  • Rhinovirus/Influenza
  • Drug-resistant Bacteria
  • Ebola
  • Mosquito Borne Diseases
Advanced Sustainable Research
  • Pollution Control
  • Water Remediation
Marine Studies
  • Isolating Bioactives
  • Marine-based Drugs
  • Coral Bleaching
Advanced Material Applications
  • Functional Coatings
  • Anti-fouling
  • Biofilm Inhibiting
  • Insect Repelling Materials

Rapid Research and Analysis

GRDGS performs rapid analysis and research by using advanced algorithms and the most complete databases in the world. The team operates in a lean and efficient manner and when necessary utilizes the top Contract Research Organizations to deliver solid results that are robust and accurate.

LB Series

A broad-spectrum universal therapeutic platform to address emerging pandemics such as Alzheimer’s, diabetes, cancer, drug-resistant viruses and antibiotic-resistant bacteria. The LB Series includes:
  • Medical food for prevention, treatment, and maintenance of illnesses
  • Therapeutic drug for typical deployment against diseases
  • Therapeutic drug for atypical deployment in cases of chronic conditions

Mosquito Control

Taking on the most dangerous animal to human
“What would you say is the most dangerous animal on Earth? Sharks? Snakes? Humans? Of course the answer depends on how you define dangerous. Personally I’ve had a thing about sharks since the first time I saw Jaws. But if you’re judging by how many people are killed by an animal every year, then the answer isn’t any of the above. It’s mosquitoes. When it comes to killing humans, no other animal even comes close.”

- Bill Gates

3F (Functional Fragrance Formulation)

Mosquito-borne diseases claim thousands and millions of lives annually. While DEET is effective as mosquito repellent, it must be used in high concentration which poses risk to the user especially children and women due to its perceived toxicity and also its side effects. We are responding to dire global need for effective alternatives to DEET. We are proud to present 3F, a highly effective 2nd generation of mosquito control technology co-developed by our partner GRDGS. 3F mimics natural fragrances, is extremely safe and is designed in such a way that it can be added to a spectrum of products such as laundry detergents, body sprays, perfumes, shampoos, lotions, cosmetics etc.

Global BioLife offices

4800 Montgomery Lane Suite 210 Bethesda, MD 20814 E T (1) 301 971 3955 T (1) 301 971 3940
Unit 12.01, 12th Floor, Amcorp Trade Centre, PJ Tower, No.18, Persiaran Barat, 46050 Petaling Jaya, Selangor, Malaysia. T +603-7931 9259
7 Temasek Boulevard #29-01B, Suntec Tower One, Singapore 038987 E T (65) 6333 9181 F (65) 6333 9164
Unit B, 17th Floor, Greatmany Centre, 109-111 Queen’s Road East, Wan Chai, Hong Kong, 070 T +852-2711-1808 F +852-2711-1360